Methods of treating myeloproliferative disorders
US10918646B1 · kind B1 · utility
1Cited by
1References
30Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Oct 7, 2020 |
| Grant date | Feb 16, 2021 |
| Priority date | — |
| Expiry date | Oct 7, 2040 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P35/02
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present disclosure relates to the use of 2-((4S)-6-(4-chlorophenyl)-1-methyl-4H-benzo[c]isoxazolo[4,5-e]azepin-4-yl)acetamide, and pharmaceutically acceptable salts thereof, for treating myelofibrosis.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.